UNCY NASDAQ
Unicycive Therapeutics, Inc.
1W: -5.0%
1M: -22.2%
3M: -23.8%
YTD: -37.8%
1Y: -29.6%
3Y: -58.5%
5Y: -85.8%
$3.61
+0.03 (+0.84%)
Pre-Market: $3.52 (-0.09, -2.49%)
Weekly Expected Move ±8.7%
$3
$4
$4
$4
$5
Credit Risk of going bust: lower than 62% of companies Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99.9%), Unicycive Therapeutics, Inc. would be worth roughly what it owes.
Total debt $671K against a stock market value of $98.9M.
Distance to default 6.39 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $336K (short-term plus half of long-term), stock volatility 84.4%; Altman Z'' -1.95. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down 99.9%), Unicycive Therapeutics, Inc. would be worth roughly what it owes.
Total debt $671K against a stock market value of $98.9M.
Distance to default 6.39 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $336K (short-term plus half of long-term), stock volatility 84.4%; Altman Z'' -1.95. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (41)
Noble Financial Issues Negative Outlook for UNCY Earnings
Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
HC Wainwright Issues Optimistic Forecast for UNCY Earnings
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
ROSEN, A LEADING NATIONAL FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
Noble Financial Has Positive Forecast for UNCY Q3 Earnings
Research Analysts Set Expectations for UNCY Q3 Earnings
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
[10-Q] Unicycive Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Brookline Capital Markets Forecasts UNCY Q1 Earnings
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of “Moderate Buy” by Brokerages
Brookline Capital Markets Comments on UNCY Q2 Earnings
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
HC Wainwright Issues Optimistic Forecast for UNCY Earnings
Q1 EPS Estimate for Unicycive Therapeutics Raised by Analyst
Noble Financial Issues Positive Estimate for UNCY Earnings
Unicycive Therapeutics GAAP EPS of -$1.67 misses by $0.02
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Important Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR): Soleno Therapeutics, Inc. (NASDAQ: SLNO); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Investigating Claims on Your Behalf
Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Camping World Holdings, Inc. (NYSE: CWH); Soleno Therapeutics, Inc. (NASDAQ: SLNO); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Consensus Rating of “Moderate Buy” from Analysts
Important Notice to Long-Term Shareholders of Integer Holdings Corp. (NYSE: ITGR): Molina Healthcare, Inc. (NYSE: MOH); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Important Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf
Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf
Unicycive Therapeutics to Participate in Upcoming Investor Events in December